Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Reference: Rituximab Maintenance for Mantle Cell Lymphoma
This secondary analysis of the TRIANGLE trial investigated the efficacy and toxicity of rituximab maintenance added to ibrutinib-based regimens. Rituximab maintenance significantly
New Indication: Sacituzumab Govitecan Alone for Muscle-Invasive Bladder Cancer
The SURE-01 trial evaluated neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer. The study reported a ypT0N0 or ypT0Nx rate of 29.5% and a 24-month ev
New Reference: Trastuzumab Rezetecan for HER2+ Breast Cancer
Trastuzumab rezetecan significantly improved progression-free and overall survival compared to pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer w
New Reference: Zenocutumab for NRG1-Fusion Positive Cholangiocarcinoma
Zenocutuzumab demonstrated clinically meaningful and durable antitumor activity in patients with advanced NRG1-fusion positive cholangiocarcinoma, with an objective response rate o
New Protocol: Neoadjuvant Toripalimab with Celecoxib for MSI-H Colorectal Cancer
This randomized phase 2 study investigated the efficacy of neoadjuvant toripalimab plus celecoxib compared to toripalimab monotherapy in patients with dMMR or MSI-H locally advance
New Protocol: Talquetamab with Daratumumab for Rel/Ref Multiple Myeloma
In this phase 3 study, talquetamab plus daratumumab and pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) significantly improved progression-free and overall survival
New Protocol: Revumenib, Decitabine, and Venetoclax for Rel/Ref AML
This phase I-II study evaluated an all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia. The re
New Protocol: Polatuzumab with R-GemOx for Rel/Ref Large B-Cell Lymphoma
The POLARGO study demonstrated that Polatuzumab Vedotin plus Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) significantly improved overall survival and complete response ra
New Protocol: Pirtobrutinib with Venetoclax and Rituximab for CLL
In patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma, the addition of pirtobrutinib to venetoclax and rituximab significantly improved pro
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.